The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272-Reference-Cited by-同舟云学术

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272

Published:2007-02-19 Issue:34 Volume:26 Page:5023-5027
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Minami Y,Shimamura T,Shah K,LaFramboise T,Glatt K A,Liniker E,Borgman C L,Haringsma H J,Feng W,Weir B A,Lowell A M,Lee J C,Wolf J,Shapiro G I,Wong K-K,Meyerson M,Thomas R K

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/1210292.pdf

Reference26 articles.

1. Azam M, Latek RR, Daley GQ . (2003). Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831–843.

2. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA . (1987). erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 178–182.

3. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. (2005). ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102: 3788–3793.

4. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237–2246.

5. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M et al. (1998). Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 78: 766–774.

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Loss of Rb1 Associated With the Onset of Acquired Resistance to Trastuzumab Deruxtecan in TP53-/HER2-Mutated Non–Small-Cell Lung Cancer: Case Series;JCO Precision Oncology;2023-02

2. Targeted therapy;Medicines for Cancer;2023

3. Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling;Nature Cancer;2022-07-26

4. Significance of TP53 Mutational Status-Associated Signature in the Progression and Prognosis of Endometrial Carcinoma;Oxidative Medicine and Cellular Longevity;2022-07-06

5. Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B;JCO Precision Oncology;2022-07